UNSPSC 51123114: Procainamide

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C13H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) L39WTC366D, chemically known as benzamide, p-amino-n-(2-(diethylamino)ethyl)- but more generally known as procainamide, which bears US NIH Compound Identifier 4913. European Medicines Agency schedules Procainamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10055MIG.

UNSPSC 51123114 Procainamide, a Commodity code, covers emergency life-support pharmaceuticals and cardiac medications procured by state health agencies, municipal fire and rescue services, and cooperative purchasing alliances for direct supply to hospital systems, emergency departments, and pre-hospital care providers. State and local governments buy these medications through sealed competitive bid processes, standing supply agreements with wholesalers, and multistate cooperative purchasing vehicles that aggregate demand across dozens of jurisdictions. Issuing bodies include municipal purchasing departments (fire rescue operations), state health and human services commissions, and regional purchasing alliances like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). The work itself splits between unit-level procurement—sealed bids for specific medication quantities with firm pricing, inventory management, expiration-date warranty, and rapid delivery—and strategic vendor development through RFIs and RFPs that establish manufacturer relationships and pricing models for ongoing multistate supply chains.

Geographic activity centers on Texas (Texas Health and Human Services Commission RFI for direct-to-manufacturer pharmacy initiatives posted April 2026) and Minnesota through MMCAP's multistate network (RFP for generic pharmaceuticals due March 26, 2026, serving Minnesota and Oregon participants), with municipal procurement in Florida (City of Tampa Fire Rescue sealed bid 26-P-00188 for advanced life support medications due April 8, 2026, estimated value $40,000, with a Small Local Business Enterprise sheltered-market 5 percent discount). The Tampa solicitation exemplifies the operational level: 370 units of Labetalol HCI, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg, and 1,020 units of Diltiazem 25mg, all with nine-month minimum expiration dates, FOB delivery within ten days, and one-year firm pricing with two optional renewals. Vendors must hold $5 million general liability and provide OSHA Safety Data Sheets; municipal and cooperative awards typically run twelve to twenty-four months with performance penalties for reporting and delivery failures. The market shows steady quarterly procurement activity across emergency medicine and pharmacy benefit supply channels, with both tactical unit buys and strategic RFPs announcing future formal solicitations.